Your shopping cart is empty!
Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
Catalog: | HY-116175 |
Brand: | MCE |
CAS: | 156635-05-1 |
MDL | MFCD00930515 |
---|---|
Molecular Weight | 380.87 |
Molecular Formula | C22H21ClN2O2 |
SMILES | O=C(C1=CC=C(C=C1)Cl)N2CC/C(CC2)=C\C3=CC=C(C=C3)C4=NCCO4 |
BIBB 515 is a potent, selective and orally active 2,3-oxidosqualene cyclase (OSC) inhibitor with ED 50 values of 0.2-0.5 mg/kg and 0.36-33.3 mg/kg in rats and mice (1-5 hours), respectively. BIBB 515 exerts lipid-lowering effect mainly by inhibiting the production of low-density lipoprotein (LDL) [1] .
2,3-oxidosqualene cyclase (OSC) [1]
Sterol synthesis, 2,3-oxidosqualene cyclase activity, HMGCoA reductase activity, and the specificity of BIBB 51 5 versus 2,3-oxidosqualene cyclase are measured in intact HepG2 cells or cell homogenates.Concentration-dependent inhibition of cholesterol biosynthesis by BIBB 515 as monitored by [ 14 C]-acetate incorporation into digitonin precipitable sterols could be demonstrated in HepG2 cells (ED 50 = 4.11 nM). A similar inhibition of OSC activity (ED 50 = 8.69 nM) is seen in HepC2 cell homogenates. No inhibition of HMGCoA reductasc could be measured in HepG2 cell homogenates at concentrations of BIBB 515 up to 1 and 10 μM [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
BIBB 515 (16.0-148.2 mg/ kg; oral administration; daily; for 40 days; male golden Syrian hyperlipemic hamsters) treatment shows dose-dependent lipid-lowering activity in normolipemic hamsters (-19% for total cholesterol and -32% for VLDL + LDL cholesterol) and in hyperlipemic hamsters (-25% for total cholesterol and -59% for LDL-cholesterol) [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: | Male golden Syrian hyperlipemic hamsters (~100 g) [1] |
Dosage: | 16.0 mg/ kg, 49.7 mg/ kg, and 148.2 mg/ kg |
Administration: | Oral administration; daily; for 40 days |
Result: | Dose-dependent lipid-lowering activity was seen in normolipemic hamsters after 11 days treatment (-19% for total cholesterol and -32% for VLDL + LDL cholesterol at 55 mg/kg/day) and in hyperlipemic hamsters after 25 days (-25% for total cholesterol and -59% for LDL-cholesterol at 148 mg/kg/day). |
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT02266485 | Boehringer Ingelheim |
Healthy
|
July 1998 | Phase 1 |
NCT02266498 | Boehringer Ingelheim |
Healthy
|
June 1998 | Phase 1 |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 2.5 mg/mL ( 6.56 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.6256 mL | 13.1278 mL | 26.2557 mL |
5 mM | 0.5251 mL | 2.6256 mL | 5.2511 mL |
10 mM | --- | --- | --- |
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.